Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2018-04-17 Regulatory Filings
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Mayne Pharma opens new US manufacturing facility 2 pages 269.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about the official opening of a new manufacturing facility by Mayne Pharma. It details the features, capabilities, and strategic benefits of the new facility, including capacity expansion and technology transfers. There is no financial data, regulatory filing references, or report attachments. The content is a corporate announcement about operational expansion rather than a financial report, management change, or regulatory filing. Therefore, it fits best under the category of a general Regulatory Filing (RNS) as it is a regulatory announcement but does not match any more specific category like Annual Report, Earnings Release, or Capital Update.
2018-04-17 English
Mayne Pharma launches Amiodarone 200mg tablets in the US 1
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about the launch of a pharmaceutical product (amiodarone tablets) in the United States by Mayne Pharma. It provides details about the product, manufacturing facility, and company background. There is no financial data, no regulatory filing references, no voting results, no management changes, no earnings information, and no detailed report content. The document is a corporate announcement about a product launch, which does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. Given the nature of the content, it is best classified as a Regulatory Filing (RNS), which serves as a general category for miscellaneous announcements that do not fit other specific categories.
2018-04-16 English
Appendix 3B 9 pages 690.6KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is an announcement related to the issue of new securities, specifically the issuance of 740,000 fully paid ordinary shares by Mayne Pharma Group Limited. It includes detailed information about the securities issued, their terms, issue price, purpose (long-term incentive), and compliance with ASX listing rules. The document also contains a quotation agreement section and details about employee options issued under an employee share option plan. The document is a formal announcement to the ASX (Australian Securities Exchange) regarding a new share issue and application for quotation of additional securities. It does not contain financial statements, management discussion, or audit information. It is not a report but an announcement of a capital change event. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (12,909 characters) supports that it is a detailed announcement rather than a brief notice or a full report.
2018-04-09 English
Appendix 3B 9 pages 146.0KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It contains detailed information about the issuance of new securities, including the number of shares issued, terms of the securities, issue price, purpose of the issue, and details about employee options. The document references compliance with ASX (Australian Securities Exchange) rules and the Corporations Act, indicating it is a formal announcement related to capital raising and securities issuance. There are no financial statements or management discussion of financial results, so it is not an Annual Report or Interim Report. It is not a proxy statement, voting results, or a call transcript. The content clearly fits the category of a capital or financing update, specifically about new share issuance and securities quotation. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (over 13,000 characters) and detailed content support a high confidence in this classification.
2018-04-08 English
Change in substantial holding 7 pages 253.2KB
Major Shareholding Notification Classification · 100% confidence The document text includes references to changes in interests of substantial holders, with multiple mentions of shareholdings and percentages. The subject line indicates 'Form 604 Change of Interests of Substantial Holder,' which is a regulatory filing notifying changes in significant share ownership levels. The document is relatively short (3321 characters) and contains tables listing shareholders and their holdings. There is no indication of financial statements, management discussion, or other report types. This fits the definition of a Major Shareholding Notification (MRQ).
2018-03-27 English
Mayne Pharma launches generic Quartette in the US 1
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about the launch of a generic pharmaceutical product by Mayne Pharma. It contains no financial statements, no detailed financial analysis, no regulatory certifications, or voting results. It is a corporate announcement about a product launch, which fits best under general regulatory announcements or miscellaneous filings. The document length is short (2543 characters), and it is not a report or presentation. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Investor Presentation. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2018-03-26 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.